This clinical trial is focused on studying progressive myopia, a condition where a child’s vision becomes increasingly nearsighted over time. The study will use Atropine Sulfate eye drops in two different low doses: 0.02% and 0.01%. These eye drops are designed to be used in the eyes to help control the progression of myopia in children.

The purpose of the study is to determine if the 0.02% dose of Atropine Sulfate is more effective than a placebo in slowing down the worsening of myopia in children of Caucasian origin. The study will last for one year, during which the changes in the children’s vision will be monitored. The children participating in the study will receive either the 0.02% atropine eye drops, the 0.01% atropine eye drops, or a placebo.

Throughout the study, the main focus will be on measuring how much the children’s vision changes over the year. This will be done by checking the change in their eye prescription, known as cycloplegic refraction, and the length of their eyes. The study aims to provide valuable information on whether low-dose Atropine Sulfate can effectively control myopia progression in children.